Treatment of Steroid-Resistant Acute Liver Transplant Rejection With Basiliximab

Current rescue therapies for acute steroid-resistant rejection, such as OKT3 and high-dose tacrolimus, are not uncommonly associated with side effects that contribute to significant morbidity of the patient. Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 receptor antagon...

Full description

Saved in:
Bibliographic Details
Published in:Transplantation proceedings 2005-06, Vol.37 (5), p.2179-2180
Main Authors: Fernandes, M.L., Lee, Y.M., Sutedja, D., Wai, C.T., Isacc, J., Prabhakaran, K., Lim, S.G., Lee, K.H.
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Antibodies, Monoclonal - therapeutic use
Female
Graft Rejection - drug therapy
Humans
Immunosuppressive Agents - therapeutic use
Liver Function Tests
Liver Transplantation - immunology
Middle Aged
Postoperative Period
Recombinant Fusion Proteins - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Current rescue therapies for acute steroid-resistant rejection, such as OKT3 and high-dose tacrolimus, are not uncommonly associated with side effects that contribute to significant morbidity of the patient. Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 receptor antagonist on the surface of activated T lymphocytes. It has until now only been used as immunoprophylaxis in adult liver transplant patients. In this report, we describe the use of Basiliximab as rescue therapy in a case of acute steroid-resistant rejection in an adult living related liver transplant recipient.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2005.03.030